News
0 NZ Super Fund returns 13.89% in 2014, warns returns likely to wane

The New Zealand Superannuation Fund, the sovereign wealth fund set up to help smooth the cost of universal superannuation between today’s taxpayers and future generations, returned 13.89 percent over 2014, ending the year at $27.54 billion, but warns lower returns are ahead.

Last year’s return exceeded the 12.42 percent return for its passive reference portfolio benchmark and a 3.08 percent return for Treasury bills, which is the measure of the cost to the government of contributing to the fund instead of paying debt. Since inception in 2003, it has generated $11.4 billion more than the Treasury bill return of 4.66 per cent per annum and beaten its passive reference portfolio benchmark by $3.1 billion. or 1.11 per cent per annum.

Read more

News
0 NZ Super and Infratil buy RetireAustralia

New Zealand Super has joined forces with Infratil to buy major Australian aged care facility operator RetireAustralia.

The sovereign wealth fund and the asset manager will take 50% each after entering into a sale and purchase agreement worth $640.2 million.

Read more

News
0 NZ Super Fund invests US$60M in LanzaTech, taking 17% stake

The New Zealand Superannuation Fund has invested US$60 million in LanzaTech, taking a 17 percent stake, in what may be the gas fermentation company’s last capital raising before beginning to earn revenue.

The investment values the company at about US$400 million and makes the Super Fund the second-biggest shareholder behind Silicon Valley-based Khosla Ventures with 42 percent. One of Lanzatech’s original investors was Stephen Tindall’s KIWI fund, which owns 8.66 percent, while founder Sean Simpson has retained 1.4 percent.

Read more

News
0 Quadrant growth boosts cancer company listing prospect

Quadrant Private Equity has tripled the size of its latest health investment Icon Cancer Care, by buying a radiation therapy network and hospital pharmacy provider to create a $300 million business that could list in late 2015.

After buying a majority stake in the chemotherapy provider in May, Quadrant has now bought radiation therapy group Radiation Oncology Queensland (ROQ). The deal was completed on Friday and doctors and staff were notified by email on Monday night.

Read more

News
0 Media Release: Two For One Return As Promising Start-ups Boost NZ Economy

1st December 2014

Two For One Return As Promising Start-ups Boost NZ Economy

The latest investment report from the New Zealand Venture Investment Fund (NZVIF) shows that the emergence of promising start up companies, backed by the local venture capital market, is boosting the country’s economy, says New Zealand Private Equity and Venture Capital Association (NZVCA) Executive Director Colin McKinnon.

Commenting on last week’s release of the NZVIF Investment Report, Colin McKinnon says: `The country’s venture capital industry can hold its head up high internationally in terms of the recent returns on investment. We are clearly tracking international trends with our potential for good returns.’

1 2 3 17